Cidara Therapeutics has received U.S. FDA Breakthrough Therapy designation for CD388, a long-acting antiviral conjugate designed for the prevention of seasonal influenza A and B. This regulatory milestone is supported by Phase 2b data showing statistically significant prevention of flu in healthy adults and targets high-risk populations who respond poorly to vaccines. The company is accelerating the development of CD388, with a Phase 3 trial now underway ahead of schedule.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.